Regulatory T cells (Tregs) represent a small subpopulation of CD4 + cells. Tregs are characterized by the expression of transcription factor Forkhead box protein 3 (FoxP3), also known as scurfin. Tregs are modulators of adaptive immune responses and play an important role in maintaining tolerance to self-antigens, providing the suppression associated with tumour microenvironment as well. These immunomodulatory properties are the main reason for the development of numerous therapeutic strategies, designed to inhibit the activity of cancer cells. However, due to Treg subpopulation diversity and its many functional pathways, the role of these cells in the cancer development and progression is still not fully understood.
Introduction
The existence of regulatory cells was postulated for the first time in the late 1960s by Nishizuka and Sakakura and in the early 1970s in the work of Gershon and Kondo. This distinct T cell population was originally characterized in mice, representing 5-10% of the peripheral CD4 + T cells [1, 2] . In humans, the Treg cell population is a small subset of CD4 + T lymphocytes (about 5%), characterized by the high-intensity expression of CD25 (CD25 high ) and with the ability to control immunity by interfering with the generation of effector function in vivo [3, 4] .
Tregs are considered to be not a homogenous population. They can be divided into several subgroups that differ in functions and can be distinguished by surface antigen expression [5, 6] .
Naturally occurring Treg cells (nTregs) arise in the thymus upon an interaction with medullary dendritic cells during the process of negative selection; they mediate suppression via cell contact-dependent mechanisms involving granzyme B/perforin or Fas/FasL pathways and constitute a major regulatory T cell subset for maintaining peripheral tolerance [7] [8] [9] [10] [11] [12] [13] .
Another population of Tregs referred as inducible or adaptive Tregs (iTreg, Tr1) is induced in the periphery in response to environmental factors and mediates suppression by contact-independent pathways through the production of TGF-beta and IL-10 [11, [14] [15] [16] .
The main phenotypic differences between nTregs and iTregs are shown in Table 1 and in Fig. 1 .
Phenotype of nTreg cells
In contrast to murine Tregs, where CD25 and FoxP3 have served as consistent and reliable markers for Treg identification, human Tregs are difficult to determine the phenotype, due to the great diversity of markers.
nTregs were identified as CD4 + T cells expressing high levels of IL-2Ra (CD25), along with the low expression of the IL-7Ra chain (CD127), and a unique transcription factor FoxP3 which acts as a master regulator gene that induces Treg phenotype and lineage [17] .
Treg cells express several molecules such as CTLA-4 (CD152, cytotoxic T-lymphocyte-associated antigen-4), CD122, GITR (glucocorticoid-induced TNFR-related protein, glucocorticoid-induced tumour necrosis receptor), galectin 10, LAP (latency-associated peptide), ICOS (inducible costimulator), PD-1 (programmed cell death protein-1) and GARP (glycoprotein A repetitions predominant) [11, 18, [24] [25] [26] [27] [28] [29] [30] [31] .
Treg cells show elevated levels of adhesion molecules such as CD11a (LFA-1), CD44, CD54 (ICAM-1) and CD103 (aEb7 integrin) in the absence of any apparent exogenous antigenic stimulation. Yet, other markers are Toll-like receptors [25, 40, 41] .
There is some evidence suggesting that Treg cells might also exhibit a characteristic chemokine receptor profile: CXCR3, CXCR4, CCR4, CCR3, CCR5, CCR6 and CCR8. Such distinctive pattern of chemokine receptors suggests that Treg cells might be rapidly recruited to inflammation sites and thereby efficiently controls immune responses [40, 42, 43] .
Other Treg markers are LAG-3, an MHC class IIbinding CD4 homologue and neuropilin (Nrp1), which is involved in the axon guidance, angiogenesis and Tlymphocyte activation. Nrp1 was identified as an nTreg marker in mice, but in humans, this marker appears to be expressed on Treg populations present in the lymph nodes and on plasmacytoid dendritic cells (pDC) [36] [37] [38] [39] .
Another potentially significant Treg marker is CD134, which decorates activated Tregs, that is Tregs are capable of mediating suppressor functions [44, 45] . 
FoxP3
The FoxP3 gene was identified in 2001 as disease causative in Scurfy mice, which spontaneously develop severe autoimmunity/inflammation as a result of a single-gene mutation on the X chromosome [36, 46] .
Mutations of this human gene cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) which is characterized by the development of autoimmune disease in multiple endocrine organs (such as Type 1 Diabetes (T1D) and thyroiditis), inflammatory bowel disease (IBD) and severe allergy [47] [48] [49] [50] .
In humans, the FoxP3 gene maps as the Xp 11.23-Xq1 3.3 locus. FoxP3 has 11 exons, which encode a 431 amino acid protein [50] [51] [52] .
Similar to the other members of the family, FoxP3 has a forkhead domain at the C-terminus, which is responsible for the DNA binding, a leucine zipper-like domain which mediates oligomerization and a zinc finger motif with yet unknown function [51, 53, 54] . Figure 1 The major similarities and differences of human nTreg and iTreg cell surface and intracellular markers: FoxP3 -Forkhead box protein 3; TCR -T cell receptor; MHC I -major histocompatibility complex class I; MHC II -major histocompatibility complex class II; ATP -adenosine triphosphate; AMP -adenosine monophosphate; IL-2 -interleukin 2; GARP -glycoprotein A repetitions predominant; LAP -lamina-associated polypeptide; CTLA-4 (CD152) -cytotoxic T lymphocytes associated antigen-4; LAG-3 -lymphocyte activation gene-3; PD-1 -programmed cell death protein-1; ICOS (CD278) -inducible T cell costimulator; GITRglucocorticoid-induced TNFR-related protein, glucocorticoid-induced tumour necrosis receptor; GAL-1 -galectin-1; NRP1 -neuropilin 1. At the N-terminus, FoxP3 contains a proline-rich region, while other FoxP proteins have a glutamine-rich poly Q region. The N-terminus is thought to be the repressor domain [51, 54] .
The human FoxP3 has two isoforms, called FoxP3a and FoxP3b. FoxP3a is a full-length protein, whereas FoxP3b is a splice variant, lacking the region of exon 2 [52] .
FoxP3 seems to activate or repress hundreds of genes directly or indirectly through the formation of a transcription complex with other key transcription factors such as NFAT and AML1/Runx1 [51, [55] [56] [57] [58] .
FoxP3 is likely to control cell contact-dependent inhibition of the activation and proliferation of T cells, killing or inactivating APC and/or T cells, and/or suppression via cytokines such as IL-10 and TGF-b [51, 59, 60] . On the other hand, Tregs able to produce adenosine could be involved in multiple cellular functions from immune suppression to regulation of the vascular proliferation and other cellular responses. Schenk et al. have shown that Tregs produce substantially lower amount of adenosine triphosphate (ATP) than conventional CD4 + T (Tconv) cells after stimulation of the TCR. In addition, Tregs contain large amount of ectonucleotidase CD39, which enables them to rapidly degrade extracellular ATP to adenosine diphosphate (ADP) and adenosine monophosphate (AMP). Further conversion of AMP to adenosine by CD73 was proposed as probable mechanism by which Tregs might inhibit the late phase of the expansion in effector cell numbers. However, in the initial phase of Treg activation (in the first 48 h), CD39 hydrolyses ATP with low efficiency, which would enable accumulation of extracellular ATP and inhibition of the suppressive function of Tregs, while stimulating an expansion in the number of effector T cells [19, 62, 63] .
Treg in cancer
Regulatory T cells accumulating in the peripheral circulation and tumour sites of patients contribute to tumour escape from the host immune system.
Over the last few years, increased frequencies of Treg cells have been reported in the peripheral blood of patients with various types of cancer, including lung, breast, ovarian, colorectal, oesophageal, renal and gastric cancer, as well as hepatocellular carcinomas, leukaemias, lymphomas and melanomas. These studies show that Treg cells also accumulate in tumours and in peripheral blood of patients with cancer and have been implicated in tumour immune escape. What is more, many studies report that increased tumour Tregs predict reduced survival or treatment response [64] [65] [66] .
However, recent studies have provided new light on the Treg population and their dual role in cancer. Some studies show no predictive value, such as recent demonstration that tumour-infiltrating CD4 + CD25 + FoxP3 + T cells did not predict survival in renal cell carcinoma. On the other hand, CD4 + CD25 + FoxP3 + Tregs in the blood of patients with prostate cancer are more suppressive than those in the blood of patients from the control group, even if the total number does not differ [64, 67, 68] .
In several studies, particularly in haematologic malignancies, it is suggested that increased Tregs portend a favourable prognosis, as shown in recent study of specific lymphomas. An increased number of tumour-infiltrating FoxP3 + T cells predict improved survival in individuals with follicular lymphoma, and a reduced number of FoxP3 + cells predict poor survival in individuals with Hodgkin lymphoma [64, 65, [69] [70] [71] [72] .
Another possibility is that FoxP3 expression can be down-modulated in some circumstances. Schenk and colleagues observed FoxP3 + downregulation of expression and reduced Treg-mediated suppression in mice. Treg able to produce adenosine could be involved in multiple cellular functions from immune suppression to regulation of the vascular proliferation and other cellular responses. Most likely, an excess of extracellular ATP, such as exists in tumours infiltrated by inflammatory cells, serves as a recruiting signal for iTreg, which express purinergic receptors -P2X7. This process may be partly responsible for Treg accumulations at tumour sites. Once recruited, iTreg perform a variety of tasks, including the hydrolysis of endogenous ATP, which can be toxic to surrounding cells at elevated level [62] .
Our understanding of the FOXP3 + Treg role played in cancer has been further complicated by a recent discovery of another subset of CD4 + T cells, Th17 cells, which normally arise in response to extracellular pathogens such as intestinal bacteria and reside in gut-associated lymphoid tissue (GALT), but in tumours, they contribute to tumour growth. Th17, like FOXP3 + Treg, accumulate in human tumours, although the relationship between FOXP3 + Treg and Th17 is not clear. Th17 express the transcription factor RORC, which is linked to STAT-3, produce IL-17, a proangiogenic cytokine, as well as proinflammatory IL-6, IL-1 and TNF-a [11] .
It The favourable impact of FoxP3 + Treg accumulation on the prognosis has also been reported for head and neck carcinomas (HNC), which are often characterized by dense infiltrations of activated T cells. These tumours situated in the oral cavity, nasopharynx or larynx, like CRC, are permanently exposed to microorganisms and microbial flora and appear to play a significant role in the tumour progression [11, 77, 78] .
The hypothesis associated with high density of FOXP3 + Treg in CRC and, less convincingly in HNSCC, with a favourable prognosis based on the ability of these cells to suppress tumour-promoting inflammatory reactions initiated by infectious agents. Extending this hypothesis to other human solid tumours, many of which are, in fact, preceded by numerous infectious episodes, an argument for a beneficial role of Treg in regulating carcinogenesis gains strength. On the other hand, if Treg in tumours suppress antitumour immunity thereby promoting tumour progression, then their presence and activities would predict poor outcome. As a result, their presence and activities would likely interfere with immunotherapy [11] .
The frequency of Tregs is increased in chronic inflammation, in cancer patients with active disease and especially in patients with cancer after oncologic treatments. In all these cases, the increased frequency of Tregs serves as a signal for enhanced level of immune regulation to bring inflammation under control and restore the immunomodulatory equilibrium [11, 23, 79] .
Treg prognostic potential may depend not only on the numbers or function, but also on the relative abundance, specific anatomic compartmentation and even distribution within the compartment. For example, the localization pattern, but not the total number of FoxP + cells, predicted survival in stomach cancer. The Foxp3 + /granzyme B + cell ratio was a prognostic factor in Hodgkin lymphoma [64, 80, 81] .
The most probable hypothesis is that clinical and prognostic Treg significance in cancer depends on environmental factors, including infectious agents, tumourderived products and locally produced cytokines [11, 35] .
Recent work demonstrates that tumour cells secrete many factors that induce Tregs, either by direct action on T cells, or indirectly, through their effects on accessory cells, especially dendritic cells, or through the production of factors that attract Tregs locally. In vitro experiments suggest several soluble or contact-dependent tumour factors contributing to Treg generation, including cyclooxygenase-2, CD70, Gal1, TGF-b, indoleamine 2,3-dioxygenase and yet to be identified factors. Enhanced local Treg proliferation or reduced apoptosis is additional mechanism that could increase the tumour Treg number In recent years, a newly defined mechanism between extracellular vesicles (EVs) and Treg has been described. This interaction might be involved in regulation peripheral tolerance by tumour and in supporting immune evasion of human cancer.
Extracellular vesicles (EVs) including exosomes are small membrane vesicles derived from multivesicular bodies or from the plasma membrane. Most, if not all, cell types release EVs that then enter the body fluids. These vesicles contain a subset of proteins, lipids and nucleic acids that are derived from the parent cell. It is stated that EVs have important roles in intercellular communication, both local and systemic, by transferring their contents, including protein, lipids and RNAs, between cells. EVs are involved in numerous physiological processes and vesicles from both non-immune and immune cells with important role in immune regulation [89] .
Those derived from tumours extracellular vesicles (TEVs) function as pro-tumorigenic factors that can mediate intercellular communication in the tumour microenvironment and also contribute to cancer progression. The main functions of EVs in the cancer microenvironment include the following: promotion of primary cancer growth, stimulation of angiogenesis, activation of stromal fibroblasts, sculpting the cancer ECM, generation of premetastatic niche and suppression of host immune response [90] .
TEVs carry a spectrum of membrane-bound and intravesicular factors, many of which have been shown to mediate immune suppression and, represent another mechanism utilized by tumours to subvert antitumour functions of immune cells [91] [92] [93] .
Recent study suggests that TEVs have immunoregulatory properties. They induce Tregs, promote Tregs expansion, upregulate Treg suppressor function and enhance Treg resistance to apoptosis. Interactions of TEVs with Treg represent a newly defined mechanism that might be involved in regulating peripheral tolerance by tumours and in supporting immune evasion of human cancers [94] .
TEVs have been also reported to induce activation and expansion of human Tregs and myeloid-derived suppressor cells (MDSC) in vitro and in vivo. Given the emerging insights into the role of the host immune system in cancer progression, considerable attention is directed at TEVs and their direct as well as indirect effects on immune cells [91, [95] [96] [97] .
Wieckowski 
Conclusions
Tregs accumulate in tumours and the peripheral blood of patients with cancer, and their increased frequency has been generally considered to be the marker of poor prognosis in cancer, presumably due to the Treg-mediated suppression of antitumour immunity. Recently, many researchers suggest that Tregs might play a dual role in carcinogenesis. The clinical and prognostic significance of Tregs in cancer depends on the environmental factors, including infectious agents, tumour-derived products and locally produced cytokines which shape the nature of immune responses, including Treg generation, recruitment and survival.
Understanding and controlling the mechanisms of tumour-induced suppression of host immune responses in different cancers and environments could be a crucial aspect in future anticancer approaches. 
